S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
The Day of Financial Reckoning Is Near (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
The Day of Financial Reckoning Is Near (Ad)
NASDAQ:CYTK

Cytokinetics - CYTK Stock Forecast, Price & News

$50.30
+0.83 (+1.68%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$50.00
$51.08
50-Day Range
$38.54
$53.54
52-Week Range
$29.10
$54.74
Volume
850,601 shs
Average Volume
1.58 million shs
Market Capitalization
$4.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.00

Cytokinetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
17.3% Upside
$59.00 Price Target
Short Interest
Healthy
12.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.00
Upright™ Environmental Score
News Sentiment
0.38mentions of Cytokinetics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$3.04 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.80) to ($4.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

550th out of 1,117 stocks

Pharmaceutical Preparations Industry

273rd out of 550 stocks

CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

CYTK has been the topic of several research reports. Needham & Company LLC increased their price target on shares of Cytokinetics from $52.00 to $60.00 in a research report on Thursday, May 5th. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Cytokinetics in a research note on Tuesday, May 24th. StockNews.com upgraded Cytokinetics from a "sell" rating to a "hold" rating in a report on Monday, August 8th. Mizuho lifted their price objective on Cytokinetics from $54.00 to $80.00 and gave the company a "buy" rating in a report on Monday, May 16th. Finally, Piper Sandler upped their target price on shares of Cytokinetics from $50.00 to $72.00 and gave the company an "overweight" rating in a research note on Thursday, June 9th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Cytokinetics has a consensus rating of "Moderate Buy" and an average price target of $59.00.

Cytokinetics Stock Up 1.7 %

CYTK traded up $0.83 on Friday, hitting $50.30. The company had a trading volume of 850,601 shares, compared to its average volume of 1,577,336. The stock has a fifty day moving average price of $43.42 and a 200-day moving average price of $39.57. The company has a debt-to-equity ratio of 1.77, a quick ratio of 9.33 and a current ratio of 9.01. Cytokinetics has a 12-month low of $29.10 and a 12-month high of $54.74. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of -19.42 and a beta of 1.14.

Cytokinetics (NASDAQ:CYTK - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.81. The firm had revenue of $88.97 million during the quarter, compared to the consensus estimate of $3.73 million. Cytokinetics had a negative return on equity of 118.37% and a negative net margin of 142.85%. The firm's revenue was up 3029.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.86) EPS. Analysts predict that Cytokinetics will post -3.8 EPS for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In related news, CEO Robert I. Blum sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $43.11, for a total value of $431,100.00. Following the sale, the chief executive officer now owns 409,124 shares of the company's stock, valued at $17,637,335.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Fady Ibraham Malik sold 21,500 shares of the business's stock in a transaction that occurred on Thursday, July 14th. The shares were sold at an average price of $43.43, for a total value of $933,745.00. Following the completion of the transaction, the executive vice president now owns 168,346 shares of the company's stock, valued at $7,311,266.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Robert I. Blum sold 10,000 shares of the company's stock in a transaction on Monday, May 16th. The stock was sold at an average price of $43.11, for a total value of $431,100.00. Following the sale, the chief executive officer now owns 409,124 shares of the company's stock, valued at $17,637,335.64. The disclosure for this sale can be found here. Insiders have sold a total of 71,500 shares of company stock valued at $3,038,445 over the last quarter. 5.00% of the stock is owned by company insiders.

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

StockNews.com Upgrades Cytokinetics (NASDAQ:CYTK) to "Hold"
Cytokinetics (NASDAQ:CYTK) Price Target Raised to $63.00
Analyst Ratings for Cytokinetics
Cytokinetics Is Showing Its Muscles on the Charts
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
8/04/2022
Today
8/13/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
253
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$59.00
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+17.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-215,310,000.00
Net Margins
-142.85%
Pretax Margin
-142.85%

Debt

Sales & Book Value

Annual Sales
$70.43 million
Book Value
$1.18 per share

Miscellaneous

Free Float
89,437,000
Market Cap
$4.74 billion
Optionable
Optionable
Beta
1.14

Social Links


Key Executives

  • Mr. Robert I. Blum (Age 58)
    CEO, Pres & Director
    Comp: $1.08M
  • Mr. Ching W. Jaw (Age 59)
    Sr. VP & CFO
    Comp: $645.6k
  • Dr. Fady Ibraham Malik FACC (Age 58)
    M.D., Ph.D., Exec. VP of R&D
    Comp: $733.08k
  • Mr. Andrew M. Callos (Age 66)
    Exec. VP & Chief Commercial Officer
    Comp: $411.85k
  • Dr. James A. Spudich Ph.D. (Age 80)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Jeff Lotz
    VP of Sales & Operations
  • Mr. Robert C. Wong (Age 54)
    VP & Chief Accounting Officer
  • Ms. Joanna Siegall
    Associate Director of Corp. Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer
  • Mr. Scott R. Jordan
    Sr. VP of Global Marketing & Commercial Strategy













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2022?

10 brokerages have issued 12 month target prices for Cytokinetics' stock. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they expect the company's share price to reach $59.00 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2022?

Cytokinetics' stock was trading at $45.58 at the start of the year. Since then, CYTK stock has increased by 10.4% and is now trading at $50.30.
View the best growth stocks for 2022 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.81. The biopharmaceutical company had revenue of $88.97 million for the quarter, compared to analysts' expectations of $3.73 million. Cytokinetics had a negative trailing twelve-month return on equity of 118.37% and a negative net margin of 142.85%. The company's revenue was up 3029.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.86) EPS.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pictet Asset Management SA (2.58%), Lazard Asset Management LLC (1.98%), Artal Group S.A. (1.35%), Franklin Resources Inc. (1.16%), Northern Trust Corp (1.03%) and Principal Financial Group Inc. (0.79%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $50.30.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $4.74 billion and generates $70.43 million in revenue each year. The biopharmaceutical company earns $-215,310,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 253 workers across the globe.

When was Cytokinetics founded?

Cytokinetics was founded in 1997.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.